COLUMN: Six Members of the U.S. House that 340B Stakeholders Should Keep an Eye on in 2025

Ted Slafsky, publisher and CEO of 340B Report, writes a column on the most important U.S. House members for 340B stakeholders.
There are 435 members of the U.S. House and 100 U.S. Senators, and each one of them can influence the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Column: Post Election Analysis: Implications for the 340B Program

Ted Slafsky, publisher and CEO of 340B Report, writes a column on the impact of the recent elections on the 340B program.
With President-elect Donald Trump’s (R) big victory and the GOP takeover of the U.S. Senate in last week’s elections, we [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Column: Much-Needed Wins for 340B Providers but Challenges Could Be Lurking

Ted Slafsky, publisher and CEO of 340B Report, writes about litigation over state 340B contract pharmacy laws.
After a long period in which many 340B providers felt helpless, the last month has brought two major wins. First, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Column: CMS Should Heed the Advice of 340B Community on Medicare Negotiations

Ted Slafsky, publisher and CEO of 340B Report, writes about Medicare drug price negotiations and the 340B program.
The Biden administration deserves credit for playing a key role in passing the first law in history to allow the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Column: Unilateral Imposition of Rebate Model for the 340B Program is a Non-Starter

Ted Slafsky, publisher and CEO of 340B Report, writes about a major drugmaker's proposed 340B rebate model.
If things were not difficult enough already for 340B providers, hospitals woke up on Friday morning to an announcement that [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Column: Three Key Observations from Efforts to Restore 340B Discounts in the States

Ted Slafsky, publisher and CEO of 340B Report, writes about efforts to pass state 340B contract pharmacy access legislation.
After six months of heated battles in the states to restore access to 340B drug discounts in the contract pharmacy [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Lilly Adds Significant New Restrictions on 340B Contract Pharmacy Access; Alleges Lack of Oversight by HRSA, Pharmacies and TPAs

Lilly wordmark on top of building
Pharmaceutical giant Eli Lilly has significantly escalated its restrictions on access to 340B pricing in the contract pharmacy setting, the company announced June 19 on the drug industry vendor site 340B ESP.
Pharmaceutical giant Eli Lilly has significantly escalated its restrictions on access to 340B pricing in the contract pharmacy setting, the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

COLUMN: After 340B Hearing and New Bills Emerging; The Likely Path Forward

The latest column from Ted Slafsky, publisher and CEO of 340B Report, addresses the likeliest path forward for 340B federal legislation.
Despite its importance, the 340B drug discount program rarely ever goes under the Congressional spotlight.  In fact, until the June [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Column: Momentum Continues in States on Contract Pharmacy Access

340B Report Publisher and CEO Ted Slafsky addresses advocacy battles around 340B contract pharmacy state laws.
In last month’s column, I wrote about a reprehensible campaign by 340B opponents to tie this vital drug discount program [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

COLUMN: Despite 340B Opponents’ Unprecedented Tactics, Many States Progress on Contract Pharmacy Protection Legislation

Ted Slafsky, publisher and CEO of 340B Report, writes about the surge in state 340B legislation in his latest column.
After over 30 years of working in Washington, D.C., I have become accustomed to the expression “politics ain’t beanbag.” The [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live